Experimental Novartis drug slows kidney cancer
WASHINGTON (Reuters) - An experimental drug from Swiss drugmaker Novartis slowed the progression of kidney cancer in patients whose tumors returned after initial chemotherapy, researchers reported on Friday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=LXZktV" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=LXZktV)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=iQNw5H" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=iQNw5H) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=IeTBJh" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=IeTBJh) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=d58C2h" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=d58C2h)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/291933228" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/291933228/idUSN1643506320080516